Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Cangene Corporation
ClinicalTrials.gov Identifier:
NCT00360737
First received: July 19, 2006
Last updated: June 8, 2011
Last verified: June 2011
  Purpose

The primary purpose of the study is to evaluate the safety of the 7 Botulinum Antitoxin Serotypes derived from horses using various laboratory measurements, clinical examinations and adverse events. In addition, following intravenous (injected into the vein) administration assessing how much 7 Botulinum Antitoxin remains in the body.


Condition Intervention Phase
Healthy
Biological: Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Phase 1

Cangene Corporation has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Pharmacokinetics of a Heptavalent Equine-derived Botulinum Antitoxin (NP-018)

Further study details as provided by Cangene Corporation:

Primary Outcome Measures:
  • Serum for Antitoxins and Pk analysis [ Time Frame: (Day 2 Screening, 30 minutes, 4 hours, 8 hours, Day 1 [24 hours], Day 3, Day 7, Day 14, Day 21, Day 28 or early withdrawal) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Blood Chemistry Assessment [ Time Frame: (Day 1 Screening, Baseline, Day 7 and Day 28 or early withdrawal) ] [ Designated as safety issue: Yes ]
  • Urinalysis Assessment ( [ Time Frame: Day 1 Screening, Baseline, Day 7 and Day 28 or early withdrawal) ] [ Designated as safety issue: Yes ]
  • Physical Examination [ Time Frame: (Day 1 Screening, Day 28 or early withdrawal) ] [ Designated as safety issue: Yes ]
  • Concomitant Medications [ Time Frame: (Day 1 Screening, Day 2 Screening, Baseline, Day 0 [Time 0], 30 minutes, 4 hours, 8 hours, Day 1 [24 hours], Day 3, Day 7, Day 14, Day 21, Day 28 or early withdrawal) ] [ Designated as safety issue: Yes ]
  • Vital Signs [ Time Frame: (Day 1 Screening, Baseline, Day 0 [Time 0], 30 minutes, 4 hours, 8 hours, Day 1 [24 hours], Day 7, Day 28 or early withdrawal) ] [ Designated as safety issue: Yes ]
  • Adverse Events [ Time Frame: (Day 1 Screening, Day 2 Screening, Baseline, Day 0 [Time 0], 30 minutes, 4 hours, 8 hours, Day 1 [24 hours], Day 3, Day 7, Day 14, Day 21, Day 28 or early withdrawal) ] [ Designated as safety issue: Yes ]
  • Hematology Assessment [ Time Frame: (Day 1 Screening, Baseline, Day 3, Day 7, Day 14, Day 21, Day 28 or early withdrawal) ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: July 2006
Study Completion Date: April 2010
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: NP-018
Subjects received one or two vials of NP-018 administered intravenously.
Biological: Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Biological/Vaccine NP-018 Experimental with 8 Cohorts of 5 Subjects each evaluating 2 Dosage levels of 1 or 2 vials of NP-018 administered intravenously.
Other Name: Botulism Antitoxin (BAT)

Detailed Description:

Clostridial toxins are amongst the most toxic substances known to science (Middlebrook, 1995). In the United States and other countries, human exposure to Clostridium botulinum toxins usually occurs through food poisoning, wound botulism and colonizing infections in neonates. Recent events have heightened concern about the possibility of botulinum toxins being used in a bioterrorist attack. In order to be prepared for a biological attack as well as the usual human exposures, numerous therapeutic products have been or currently are undergoing development to treat or prevent botulism, including the use of human or equine derived antibodies for post-exposure prophylaxis of botulinum toxin exposure (Gelzleichter et al, 1999; Hibbs et al, 1996; Metzger and Lewis, 1979 and Keller and Stiehm, 2000).

Botulinum antitoxins have been in use to treat adult exposure to botulinum toxin for at least 40 years (Cupo et al, 2001). The use of botulinum antitoxins to treat individuals exposed to botulinum toxin is similar to the use of passive immune therapy with immune globulins collected from immunized or convalescing human donors to treat a wide range of bacterial and viral infectious diseases (Chippaux et al, 1998).

NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from plasma obtained from horses that have been immunized with a specific subtype of botulinum toxoid and toxin. Each individual horse is immunized against a single botulinum toxin subtype. Plasma is pooled from horses that have been immunized with the same botulinum toxin subtype. For each antitoxin serotype (A-G), a despeciated product will be produced by pepsin digestion of the IgG monomer in the equine plasma, yielding predominantly F(ab¢)2 fragment. Following the formulation, the seven antitoxin serotypes will be blended into a heptavalent product and filled into single-use vials.

The present clinical study is intended to assess the pharmacokinetics and safety of NP 018 following intravenous administration. The pharmacokinetics of NP 018 will be comparable to other equine derived antitoxin products. NP 018 will be safe to administer to normal healthy volunteers.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body-mass index of 20 to 30 with minimum body weight of 111 lb (50 kg).
  • For female subjects that are not surgically sterilized, willingness to use an effective method of contraception throughout the trial including:
  • Using hormonal contraception (oral or injectable or implant) continuously for 3 months prior to the start of the trial and willing to continue to use hormonal contraception throughout the entire trial.
  • IUD inserted at least 2 months prior to dosing.
  • For female subjects who are postmenopausal less than 2 years an FSH >= 40 mIU/mL must be obtained. IF the FSH is < 40 mIU/mL the subject must agree to use an acceptable form of contraception (see above for acceptable forms of contraception.
  • Normal and healthy as determined by medical history, physical examination, ECG, vital signs and test of liver, kidney and hematological functions.
  • Written Informed Consent

Exclusion Criteria:

  • Any known or documented allergies to horses (e.g. rash, wheezing, rhinitis etc. after exposure to horses)
  • Any known or documented allergies to horse serum (observation of adverse events after treatment with any kind of products containing horse serum)
  • Any severe food allergies, seasonal allergies or hay fever requiring therapy such as treatment with immunosuppressive drugs
  • Known acute or chronic asthma requiring treatment with immunosuppressive drugs
  • History of hypersensitivity to blood products derived from a human or equine source
  • Heavy smokers (>10 cigarettes a day)
  • Use of nicotine containing products
  • Use of any investigational product within the past 30 days
  • Pregnancy or lactation
  • Positive serological test for HIV, HBV, or HCV
  • History of, or suspected substance abuse problem (including alcohol) or failure of alcohol or drug screen at screening or at baseline
  • Individuals with a history of allergy to latex or rubber
  • Hemoglobin level of < 12 g/dL.
  • Significant blood loss or blood donation within 56 days prior to dosing.
  • Any plasma donation within 7 days prior to dosing.
  • Demonstrated potential for allergic reaction to NP-018 based on positive horse dander (E3) IgE test or positive NP-018 skin sensitivity test prior to dosing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00360737

Locations
United States, Arizona
MDS Pharma Services
Phoenix, Arizona, United States, 85044
Sponsors and Collaborators
Cangene Corporation
Investigators
Principal Investigator: Mark J. Allison, M.D. MDS Pharma Services
  More Information

Publications:
Responsible Party: Fran Yadao, Manager Clinical Operations, Cangene Corp.
ClinicalTrials.gov Identifier: NCT00360737     History of Changes
Other Study ID Numbers: AA24424 BT-001
Study First Received: July 19, 2006
Last Updated: June 8, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Cangene Corporation:
Clinical Trials
Investigational Drug
Healthy Volunteers
Botulinum Antitoxin
Phoenix, Arizona

Additional relevant MeSH terms:
Antitoxins
Botulinum Antitoxin
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2014